S

tung by reports of backpedaling on a pledge to limit drug price hikes, AbbVie (ABBV) insisted on Tuesday that it will stick to just one, single-digit price increase next year.

The statement came a day after news reports — including ours — indicated the drug maker would abandon its commitment to keep all price increases below 10 percent and raise prices only once a year, although AbbVie maintained its pledge referred only to this year. The original source for the stories was a report from a Wall Street securities analyst, who summarized AbbVie remarks following a meeting with company management last week.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy